KalVista製藥 KALV 深 滬
等待開盤 03-26 09:30:00 美东时间
17.14
+0.680
+4.13%
華盛通- 最 高17.665
- 今 開17.17
- 成交量 172.00万股
- 最 低 16.44
- 昨 收 16.46
- 總市值 8.66亿
- 52周最高 19.00
- 市盈率 靜 --
- 換手率 3.40%
- 52周最低 9.235
- 委 比 -81.97%
- 總股本 5054.63万
- 歷史最高 45.00
- 量 比 1.88
- 振 幅 7.44%
- 歷史最低 4.12
- 每 手 1
- 風險率 1.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
KalVista Pharmaceuticals beats Q4 topline estimates
KalVista Pharmaceuticals press release (KALV): Q4 GAAP EPS of -$2.03 may not be comparable to estimates. Revenue of $49.08M beats by $16.79M. As of December 31, 2025, the Company had cash, cash equiva...
03-25 19:09
KalVista Pharma Reported $49.1M In Net Product Revenue For The Eight Months Ended December 31, 2025, Held $300.2M In Cash Balance
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year
03-25 19:03
KalVista FY2025 transition period loss per share narrows 11.74% to $(2.03); revenue rises to $49 million
KalVista FY2025 transition period loss per share narrows 11.74% to $(2.03); revenue rises to $49 million FY2025 eight-month transition period net loss narrowed 0.84% to $110 million. FY2025 eight-month transition period loss per share narrowed to $2.03 from $2.30 per share. FY2025 eight-month transi
03-25 19:00
KalVista Pharmaceuticals to Host Fiscal 2025 Eight-Month Financial Results Call and Corporate Update
KalVista Pharmaceuticals to Host Fiscal 2025 Eight-Month Financial Results Call and Corporate Update KalVista will host a conference call and webcast on March 25, 2026, at 8:30 a.m. ET to review its eight months fiscal year 2025 financial results and provide a corporate update. The webcast will be a
03-18 19:00
KalVista highlights new EKTERLY sebetralstat trial data showing high patient satisfaction and earlier HAE attack treatment
KalVista highlights new EKTERLY sebetralstat trial data showing high patient satisfaction and earlier HAE attack treatment KalVista Pharmaceuticals Inc. announced new data from its sebetralstat clinical trial program evaluating EKTERLY (sebetralstat), an oral on-demand treatment for hereditary angio
03-02 20:00
Most and least shorted healthcare stocks with up to $2B market cap
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV) and Intellia (NTLA) have become...
02-17 02:05
KalVista Pharmaceuticals Announces New Clinical Data on EKTERLY® (sebetralstat) for Hereditary Angioedema at AAAAI 2026
KalVista Pharmaceuticals Announces New Clinical Data on EKTERLY® (sebetralstat) for Hereditary Angioedema at AAAAI 2026 KalVista Pharmaceuticals Inc. has announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting,
02-12 20:01
KalVista Pharmaceuticals Grants Stock Options to New Employees
KalVista Pharmaceuticals Grants Stock Options to New Employees KalVista Pharmaceuticals Inc. has granted inducement stock options to six newly-hired employees, allowing them to purchase a total of 96,750 shares of KalVista common stock. The options have an exercise price equal to the closing price o
02-03 20:00
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
